Statin Therapy for Ischemic and Nonischemic Cardiomyopathy

Inclusion Criteria: * Ischemic Cardiomyopathy (as defined above) with ejection fraction \< 35% * Non-ischemic Cardiomyopathy with ejection fraction \< 35% * NCEP ATPIII indication for therapy with a statin drug * No statin therapy within previous 6 months of study enrollment * Prescribed stable doses of standard heart failure therapies including beta blocking agents, angiotensin converting enzyme inhibitors or angiotensin receptor blockers, and diuretic agents as required Exclusion Criteria: * Pregnant or lactating * Myocardial infarction within 6 months preceding study enrollment * Primary valvular heart disease * Surgical or catheter based revascularization within the preceding 6 months * Documented viral or inflammatory myocarditis or cardiomyopathy * Peripartum cardiomyopathy * Infiltrative cardiomyopathies * Chemotherapy associated cardiomyopathy * Without indication for statin therapy * Contraindication to statin therapy including hepatic dysfunction, history of rhabdomyolysis or prior intolerance of statin therapy * Contraindication to magnetic resonance imaging